1 citations
,
May 2021 in “International Journal Of Medical Science And Clinical Invention” This review discusses the potential risk mechanisms for COVID-19 in women with polycystic ovarian syndrome due to hyperandrogenism and calls for further research, but reports no new findings.
1 citations
,
February 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that electrospinning membranes with smaller fiber diameters significantly improved skin wound healing by promoting cell proliferation and encouraging reparative macrophage transformation.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” This study suggests that NKG2D+ Vδ1 T cells may contribute to hair follicle pathology in alopecia areata by recognizing stressed keratinocytes and inducing immune privilege collapse.
1 citations
,
October 2013 in “The Journal of Dermatology” This letter to the editor discusses the immune response related to hair loss in a case of atypical drug-induced hypersensitivity syndrome but reports no new research findings.
1 citations
,
January 1982 in “International Journal of Immunopharmacology” Too much zinc can cause hair loss and weaken the immune system.
August 2026 in “Frontiers in Medicine” This study suggests that low-dose IL-2 and IL-15 may help restore immune tolerance in alopecia areata by maintaining Treg cell function, presenting a potential new treatment strategy.
This study found that Plakophilin 1 regulates innate immune responses in keratinocytes by controlling RNA helicase activity, balancing inflammation during epidermal immune challenges.
August 2026 in “Journal of Personalized Medicine” This narrative review proposes the concept of "repigmentation competence" for vitiligo lesions, suggesting that therapy responses are influenced by lesion-specific biological factors related to immune, regenerative, regulatory, and microenvironmental processes, and highlights the emerging role of combination therapies targeting these pathways.
August 2026 in “The Journal of Dermatology” In this review, the authors summarize recent findings on dermal white adipose tissue (dWAT), highlighting its crucial role in the hair follicle microenvironment by regulating inflammation and immune responses, thus influencing hair regeneration.
July 2026 in “Frontiers in Immunology” This review explores the mechanisms of wound-induced hair follicle neogenesis in mice, discussing its potential to inform precision therapies for alopecia and scarless wound healing, but reports no new clinical results.
July 2026 in “Expert Review of Clinical Immunology” This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.
July 2026 in “Expert Review of Clinical Immunology” This article reviews the roles of dendritic cells in alopecia areata and highlights emerging precision therapies that target these cells, reporting no new experimental findings.
July 2026 in “Plastic & Reconstructive Surgery Global Open” This study found that intradermal injections of plant-derived exosomes in adults with early-stage alopecia increased stem cell activity, activated Wnt signaling pathways, and reduced certain immune cell populations, providing insights into their role in hair follicle regeneration and suggesting potential for hair restoration therapy.
June 2026 in “kerbala journal of pharmaceutical sciences” In this case-control study, individuals with alopecia areata showed significantly elevated levels of inflammatory markers IL-4, IFN-γ, and CRP, as well as reduced serum Folate and Ferritin, suggesting the condition's multifactorial pathophysiology involves immune activation, systemic inflammation, and micronutrient deficiencies.
June 2026 in “Frontiers in Bioengineering and Biotechnology” This review outlines the transition from simple hair follicle organoids to immune-competent microphysiological systems, addressing limitations in replicating native hair follicle immune features and discussing their applications in disease modeling and regenerative medicine.
June 2026 in “Journal of Investigative Dermatology” Aging weakens sweat glands due to reduced support from immune cells, but treatments may help restore function.
April 2026 in “Cytotherapy” This study identifies macrophage-mediated immune signaling as a crucial factor in activating hair follicle stem cells and promoting hair regeneration, offering a new model for testing regenerative therapies for alopecia.
April 2026 in “Frontiers in Medicine” This study found that activating hair follicle resident T cells in a human organ culture can induce an alopecia areata-like immune response, and that the drug farudodstat partially reduced this effect.
In this study, the researchers used a human hair follicle model to demonstrate that T cell stimulation can induce an alopecia areata–like phenotype, with cell proliferation and immune privilege collapse; however, the DHODH inhibitor farudodstat partially mitigated these effects by reducing T cell proliferation.
April 2026 in “Frontiers in Cell and Developmental Biology” This study found that PGRP-S expression in mouse epidermis is specific to certain hair follicle epithelia, depending on the skin region, and can be transiently induced in flank skin hair follicle epithelium after exposure to Staphylococcus aureus, suggesting a role in environmental surveillance.
April 2026 in “World Allergy Organization Journal” This study found that allergic rhinitis is linked to a higher risk of developing androgenetic alopecia, while second-generation H1-antihistamine use was associated with a reduced risk, especially in younger patients.
April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
March 2026 in “Frontiers in Medicine” This study provides a framework for understanding different types of alopecias based on immune privilege collapse at specific follicular sites, revealing distinct patterns in immune effector programs and stromal influences depending on the alopecia type.
March 2026 in “Brazilian Journal of Microbiology” This study found that restoring the skin microbiome significantly improved hair growth and skin condition in androgenic alopecia model mice by modulating the immune-inflammatory balance, highlighting the potential of bacterial-based therapies for hair loss.
March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.
This review highlights that iron deficiency is a significant yet often overlooked contributor to the development of immune-mediated inflammatory skin diseases, suggesting that iron dysregulation may drive inflammation and metabolic imbalances in conditions like psoriasis and atopic dermatitis.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.
March 2026 in “Journal of Clinical Oncology” In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.